TY - JOUR
AU1 - Tikkinen, Kari A O
AU2 - Dahm, Philipp
AU3 - Lytvyn, Lyubov
AU4 - Heen, Anja F
AU5 - Vernooij, Robin W M
AU6 - Siemieniuk, Reed A C
AU7 - Wheeler, Russell
AU8 - Vaughan, Bill
AU9 - Fobuzi, Awah Cletus
AU1 - Blanker, Marco H
AU1 - Junod, Noelle
AU1 - Sommer, Johanna
AU1 - Stirnemann, Jérôme
AU1 - Yoshimura, Manabu
AU1 - Auer, Reto
AU1 - MacDonald, Helen
AU1 - Guyatt, Gordon
AU1 - Vandvik, Per Olav
AU1 - Agoritsas, Thomas
AB - R APID REC OMMENDATIONS Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline 1 2 3 4 5 6 Kari A O Tikkinen, Philipp Dahm, Lyubov Lytvyn, Anja F Heen, Robin W M Vernooij, 4 7 8 9 10 Reed A C Siemieniuk, Russell Wheeler, Bill Vaughan, Awah Cletus Fobuzi, 11 12 13 14 15 Marco H Blanker, Noelle Junod, Johanna Sommer, Jérôme Stirnemann, Manabu Yoshimura, 16 17 18 4 5 4 14 19 Reto Auer, Helen MacDonald, Gordon Guyatt, Per Olav Vandvik, Thomas Agoritsas What is the role of prostate-specific antigen (PSA) screen - the body of evidence. This guideline aims to promptly Full author details can be found at the end of the article ing in prostate cancer? An expert panel produced these and transparently translate potentially practice-changing Correspondence to: 1 recommendations based on a linked systematic review. evidence to usable recommendations for clinicians and K A O Tikkinen The review was triggered by a large scale, cluster ran- patients, based on the GRADE framework and following kari.tikkinen@gmail.com domised trial on PSA screening in men without a previous standards for trustworthy guidelines. Cite this as: BMJ 2018;362:k3581 doi: 10.1136/bmj.k3581 diagnosis of prostate cancer published 
TI - Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
JF - The BMJ
DO - 10.1136/bmj.k3581
DA - 2018-09-05
UR - https://www.deepdyve.com/lp/british-medical-journal/prostate-cancer-screening-with-prostate-specific-antigen-psa-test-a-YYGa4Hj8E0
SP - k3581
VL - 362
IS - 
DP - DeepDyve
ER -